Scholar Rock Holding Corporation
SRRK
주식 순위
#3505
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
주가
$40.23
시가총액
$4.90B
변동 (1일)
0.83%
변동 (1년)
43.99%
국가
US
거래 Scholar Rock Holding Corporation (SRRK)
카테고리
Healthcare
Scholar Rock Holding Corporation (SRRK)의 EPS
June 2026 기준 EPS TTM: $-3.31
Scholar Rock Holding Corporation의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-3.31입니다. 2023년 말에는 회사의 EPS가 $-1.99였으며, 이는 2022년의 EPS $-2.21와 감소입니다.
Scholar Rock Holding Corporation의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-3.31 | 34.01% |
| 2024 | $-2.47 | 24.12% |
| 2023 | $-1.99 | -9.95% |
| 2022 | $-2.21 | -38.44% |
| 2021 | $-3.59 | 29.60% |
| 2020 | $-2.77 | 53.89% |
| 2019 | $-1.80 | -42.86% |
| 2018 | $-3.15 | 125.00% |
| 2017 | $-1.40 | 53.85% |
| 2016 | $-0.91 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -623.26% |
US
|
|
| $-7.98 | 141.09% |
US
|
|
| $-5.29 | 59.82% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -938.07% |
NL
|
